Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexibuprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 5/20 | 0.66 |
| ▸ | PTGS2 known ✓ | P35354 | 5/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.66 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.66 |
| ▸ | ALB | P02768 | 1/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.66 |
| ▸ | RARB | P10826 | 1/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.66 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.66 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexibuprofen SCHEMBL8733957 | 1.00 | THRB (0.73) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Ibuprofen SCHEMBL44617 | 1.00 | THRB (0.73) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| (R)-Ibuprophen SCHEMBL29696062 | 1.00 | THRB (0.73) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| (R)-Ibuprophen SCHEMBL8579043 | 1.00 | THRB (0.73) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Ibuprofen SCHEMBL44616 | 1.00 | THRB (0.73) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Ibuprofen SCHEMBL8902943 | 0.99 | THRB (0.72) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Ibuprofen SCHEMBL8902948 | 0.99 | THRB (0.72) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Dexibuprofen SCHEMBL379398 | 0.99 | THRB (0.72) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Lysine SCHEMBL11276603 | 0.92 | THRB (0.71) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Ibuprofen SCHEMBL20775003 | 0.86 | PTGS1 (0.64) | THRBPTGS1PTGS2CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330032-A1 | MICROENCAPSULATION PROCESS AND PRODUCT | SPI PHARMA, INC. (US) | 2023-10-19 | — | — | US | claimed |
| US-11723877-B2 | Microencapsulation process and product | SPI PHARMA, INC. (US) | 2023-08-15 | — | — | US | claimed |
| EP-2629913-B1 | MICROENCAPSULATION PROCESS AND PRODUCT | SPI PHARMA INC (US) | 2020-08-26 | — | — | EP | claimed |
| US-20200170959-A1 | MICROENCAPSULATION PROCESS AND PRODUCT | SPI PHARMA, INC. (US) | 2020-06-04 | — | — | US | claimed |
| US-10561621-B2 | Microencapsulation process and product | SPI PHARMA, INC. | 2020-02-18 | — | — | US | claimed |
| US-20140044793-A1 | MICROENCAPSULATION PROCESS AND PRODUCT | SPI PHARMA, INC. (US) | 2014-02-13 | — | — | US | claimed |
| WO-2013175511-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITIONS | V.B. MEDICARE PVT. LTD. (IN) | 2013-11-28 | — | — | WO | claimed |
| EP-2629913-A1 | MICROENCAPSULATION PROCESS AND PRODUCT | SPI Pharma, INC. (US) | 2013-08-28 | — | — | EP | claimed |
| WO-2013058496-A1 | TASTE-MASKED PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION AND A PROCESS FOR THE PREPARATION THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-04-25 | — | — | WO | claimed |
| WO-2012040234-A1 | MICROENCAPSULATION PROCESS AND PRODUCT | SPI PHARMA, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| US-6551617-B1 | The coating composition comprising polyvinyl acetate, a dimethylaminoethyl methacrylate, neutral methacrylic acid ester, and an alkaline modifier for enhancing the release of the active ingredient | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-22 | — | — | US | claimed |
| EP-1276469-A2 | TASTE MASKING COATING COMPOSITION | Bristol-Myers Squibb Company (US) | 2003-01-22 | — | — | EP | claimed |
| EP-1276470-A2 | TASTE MASKING COATING COMPOSITION | Bristol-Myers Squibb Company (US) | 2003-01-22 | — | — | EP | claimed |
| US-20020197317-A1 | Taste masking coating composition | NOVARTIS AG (CH) | 2002-12-26 | — | — | US | claimed |
| WO-2001080829-A2 | TASTE MASKING COATING COMPOSITION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| WO-2001080826-A2 | TASTE MASKING COATING COMPOSITION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| EP-0523847-B1 | Taste mask coating for preparation of chewable pharmaceutical tablets | MCNEIL PPC INC (US) | 1996-04-24 | — | — | EP | claimed |
| US-5489436-A | COATING WITH COPOLYMER OF DIMETHYLAMINOETHYL METHACRYLATEAND METHACRYLATE ESTER | MCNEIL-PPC, INC. (US) | 1996-02-06 | — | — | US | claimed |
| EP-0459695-B1 | Taste masking and sustained release coatings for pharmaceuticals | MCNEIL PPC INC (US) | 1995-03-15 | — | — | EP | claimed |
| EP-0523847-A1 | Taste mask coating for preparation of chewable pharmaceutical tablets | McNEIL-PPC, INC. (US) | 1993-01-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020197317-A1 | Taste masking coating composition | TAS2R45, TAS2R42, TAS2R60 | PTGS1 3304/4885PTGS2 3542/4885THRB 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.